An overview of erythropoietin therapy

Zirapury T., van Eps C., Hawley C.M., Badve S.V. and Johnson D.W. (2013). An overview of erythropoietin therapy. In Erythropoietin: Human Production, Potential Uses and Adverse Effects (pp. 31-53) : Nova Science Publishers, Inc..

Author Zirapury T.
van Eps C.
Hawley C.M.
Badve S.V.
Johnson D.W.
Title of chapter An overview of erythropoietin therapy
Title of book Erythropoietin: Human Production, Potential Uses and Adverse Effects
Publisher Nova Science Publishers, Inc.
Publication Year 2013
Sub-type Research book chapter (original research)
ISBN 9781624171055
Start page 31
End page 53
Total pages 23
Subjects 1300 Biochemistry, Genetics and Molecular Biology
Abstract/Summary Erythropoietin, produced primarily by the kidneys, is the principal factor responsible for the regulation of erythropoiesis. Since its discovery in 1986, human recombinant erythropoietin has revolutionized the management of anemia in chronic kidney disease (CKD). Its use has resulted in substantial reduction in the requirement of blood transfusions. However, targeting higher hemoglobin levels with erythropoietin in CKD has been associated with increased risk of stroke, vascular access thrombosis, hypertension and possibly death. Pre-clinical studies suggest that erythropoietin plays a role in neovascularisation, neurogenesis and immunomodulation.Due to these pleotropic effects, erythropoietin has also been studied in various other conditions such as myocardial infarction, heart failure, stroke, acute kidney injury and spinal cord injury. The aim of this article is to review the regulation and sites of erythropoietin production, its use in clinical practice and adverse effects.
Q-Index Code B1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Book Chapter
Collection: Scopus Import
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 26 Jul 2016, 03:33:22 EST by System User